Combining magnetic resonance spectroscopy and magnetic resonance imaging in diagnosing focal brain lesions in children by Farid, Farah Naz et al.
eCommons@AKU
Section of Ophthalmology Department of Surgery
August 2017
Combining magnetic resonance spectroscopy and
magnetic resonance imaging in diagnosing focal
brain lesions in children
Farah Naz Farid
Aga Khan University, farah.naz@aku.edu
Waseem Mirza
Aga Khan University, waseem.mirza@aku.edu
Nauman Hashmani
Aga Khan University
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_ophthalmol
Part of the Surgery Commons
Recommended Citation
Farid, F., Mirza, W., Hashmani, N. (2017). Combining magnetic resonance spectroscopy and magnetic resonance imaging in
diagnosing focal brain lesions in children. Cureus., 9(8), 1-7.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_surg_ophthalmol/23
Received 05/04/2017 
Review began  05/05/2017 
Review ended  07/22/2017 
Published 08/04/2017
© Copyright 2017
Naz et al. This is an open access
article distributed under the terms of
the Creative Commons Attribution
License CC-BY 3.0., which permits
unrestricted use, distribution, and
reproduction in any medium,
provided the original author and
source are credited.
Combining Magnetic Resonance
Spectroscopy and Magnetic Resonance
Imaging in Diagnosing Focal Brain Lesions
in Children
Farah Naz  , Waseem A. Mirza  , Nauman Hashmani 
1. Fellow, The Aga Khan University 2. Associate Professor, The Aga Khan University 3. Ophthalmology,
Hashmanis Hospital
 Corresponding author: Nauman Hashmani, naumanhashmani@gmail.com 
Disclosures can be found in Additional Information at the end of the article
Abstract
Introduction
We attempted to find the sensitivity and specificity of various pediatric brain masses in the
Pakistani population while keeping histopathology or clinical diagnosis as the gold standard.
 
Methods
This was a retrospective study that was conducted from January 2007 to January 2016. We
reviewed the records of 204 patients that presented to the radiology department of Aga Khan
University Hospital (AKUH). Out of the 204, 135 pediatric patients in the 0–18 age group with
focal brain lesions who underwent magnetic resonance spectroscopy (MRS) and a biopsy or
clinical diagnosis were included. If histopathology was available, it was taken as the gold
standard test; otherwise, clinical diagnosis was considered the gold standard.
 
Results
We had a total of 135 patients, of which 71 (52.6%) were male and 64 (47.4%) were female. The
mean age represented was 7.2 ± 4.5 years with a range of 1–18 years. We found radiology
(magnetic resonance imaging (MRI) and MRS) to have a 91.7% sensitivity and a 94.3%
specificity for tumors. For leukodystrophy, there was a 64.3% sensitivity and a 97.3% specificity.
On the other hand, infection and mitochondrial disorders had sensitivities of 35.7% and 21.7%,
respectively, and specificities of 98.9% and 97.1%, respectively. The category labeled “others”
had a sensitivity of 27.4% and a specificity of 86.0%.
 
Conclusion
A combination of MRI and MRS was highly sensitive and specific for tumors. For infections,
leukodystrophy, mitochondrial disorders, and the category of “others,” it was highly specific but
poorly sensitive.
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Introduction
 
Focal lesions and parenchymal changes in the brain are traditionally diagnosed by using
neuroimaging studies, such as magnetic resonance imaging (MRI) or computed tomography
(CT) scans. These scans provide morphological data only [1], which may carry a wide
differential. Therefore, reaching a definitive diagnosis through MRI and CT scans alone
was impossible [2]. For example, an intracranial abscess and a tumor can look anatomically
identical [2]. To make this distinction, we relied on clinical judgment and an invasive
histopathological diagnosis [2]. Magnetic resonance spectroscopy (MRS) can help differentiate
between tumorous and nontumorous lesions by measuring biochemical markers in the brain [3].
It gives radiologists a tool to reach a definitive diagnosis noninvasively.
An MRS scan can help diagnose a wide variety of diseases such as tumors, cerebral ischemia,
and trauma when used as an adjunct to the MRI [3]. It measures the resonant frequencies of
various metabolites in the brain such as choline (Cho) and presents these values in a line graph
with amplitudes [4]. These values themselves are not diagnostic; however, they must be
interpreted along with the MRI [4]. Interestingly, MRS uses the same data produced by a
conventional MRI; it only differs in the way it processes the data. Therefore, with the right
scanner, this test is relatively easy to perform [4].
MRS is thought of as the future of neuroimaging [1] and has been found to be a reliable tool to
diagnose brain tumors. Not only can it differentiate between intracranial lesions [5], but it can
also aid in detecting the extent of the tumor in the nonenhancing areas of a mass [6]. Similarly,
MRS can be used for both, making initial diagnosis and for guiding treatment options in the
pediatric population [7]. This data has been widely studied in the western world but there is a
paucity of data in South Asian countries. Similarly, there is no data, to our knowledge, in
Pakistan regarding the accuracy of MRS and, therefore, we analyzed this data in our population.
Furthermore, this study has one of the largest sample sizes in the world.
We wanted to study the sensitivity and specificity of MRS in differentiating pediatric brain
masses in a large sample size in the Pakistani population while keeping histopathology or
clinical diagnosis as the gold standard.
Materials And Methods
Study Design and Patients
This retrospective study from January 2007 to January 2016 included a total of 204 patients that
presented to the radiology department of Aga Khan University Hospital (AKUH). Ethical
approval was obtained from the Ethics Committee of AKUH. Out of the 204 patients, 135
pediatric patients in the 0–18 age group with focal brain lesions who underwent MRS and a
biopsy or clinical diagnosis were included. If histopathology was available, it was taken as the
gold standard test; otherwise, clinical diagnosis was used. Informed consent was obtained
before performing MRS. We excluded all patients who did not have a radiologic diagnosis, a
histopathological analysis, or a clinical record.
MRS Sequence
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We used a single voxel method in our MRS examinations. Initially, we localized the lesion via a
contrast MRI scan, and a voxel was subsequently placed at its location. Then, the water
suppression method and the point-resolved spectroscopy (PRESS) method were utilized with an
echo time (TE) of 135 and a response time (TR) of 1500.
We looked at the spectrum of N-acetyl aspartate (NAA), Cho, and creatinine (Cr). Additionally,
we checked for the lipid or lactate peak on MRS. Ratios for Cho/Cr and Cho/NAA were
calculated. NAA is the indicator of neuronal integrity with its highest point at 2.02 ppm. Cho,
on the other hand, indicates cell turnover with its highest point at 3.22 ppm. Cr takes part in
cellular metabolism with its peak occurring at 3 ppm. Normally, no lipid or lactate peak is
observed in the brain and, even if present, they will overlap each other at 1.33 ppm [8].
Lesions can be differentiated based on the various ratios and peaks of these neurotransmitters.
A raised Cho or decreased NAA combined with a rise in Cho/Cr and Cho/NAA ratios indicates a
tumor. Additionally, lipid and lactate peaks are observed in high-grade neoplasms and
infections. The Cho/Cr and Cho/NAA ratios are unchanged in nontumorous lesions [8].
First, we categorized MRS findings into two categories, normal and abnormal. Second, we
categorized radiologic (MRS and MRI) and clinical diagnosis as normal, tumor, infection,
leukodystrophy, mitochondrial disease, and others. Histology had the same categories but we
omitted leukodystrophy and mitochondrial diseases, as we do not routinely perform biopsies
for these conditions.
Statistical Analysis
All data was collected and input into SPSS version 16.0 (IBM, NY), and this was used to carry
out all subsequent analyses. We used descriptive statistics to evaluate for sensitivity and
specificity.
Results
General Characteristics
We had a total of 135 patients, of which 71 (52.6%) were male and 64 (47.4%) were female. The
mean age represented was 7.2 ± 4.5 years within a range of 1–18 years (Table 1).
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Variable Male (n=71) Female (n=64) Total (n=135)
Age (Years)    
Mean   7.22
Standard Deviation   4.5
Range   1 - 18
Magnetic Resonance Spectroscopy (#) 71 64 135
Normal 39 27 66
Abnormal 32 37 69
Radiology* (#) 71 64 135
Normal 36 26 62
Tumor 5 12 17
Infection 3 3 6
Leukodystrophy 5 6 11
Mitochondrial Disease 5 3 8
Others 17 14 31
Histology (#) 11 14 25
Tumor 3 5 8
Infection 4 3 7
Others 4 6 10
Clinical (#) 69 61 130
Tumor 4 7 11
Infection 5 5 10
Leukodystrophy 6 8 14
Mitochondrial Disease 11 12 23
Others 43 29 72
TABLE 1: General Characteristics
*Radiology is a combination of MRI and MRS
Approximately half of the patients undergoing MRS (n=66) had normal scans. Similarly, when
combining MRI with MRS, nearly half of the patients were normal as well (n=62). On radiologic
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diagnosis, defined as the combination of MRI and MRS, we found that 17 patients had
tumors and the balance had a leukodystrophy (n=11), a mitochondrial disease (n=8), an
infection (n=6), and other diseases (n=31).
When looking at histology, 8 patients had a tumor, 7 had an infection, and 10 were categorized
as “others.” Clinically, approximately a fifth of patients had a mitochondrial disease (n=23), a
tenth had a leukodystrophy (n=14), 11 had a tumor, 10 had an infection, and 72 were
categorized as others.
Diagnostic Accuracy
We found radiology (MRS and MRI) to have a 91.7% sensitivity and a 94.3% specificity for
tumors. For leukodystrophy, it had a 64.3% sensitivity and a 97.3% specificity. Conversely,
infection and mitochondrial disorders had sensitivities of 35.7% and 21.7%, respectively, and
specificities of 98.9% and 97.1%, respectively. The category labeled “others” had a sensitivity of
27.4% and a specificity of 86.0% (Table 2).
Diagnosis Sensitivity (%) Specificity (%)
Tumor 91.7 94.3
Infection 35.7 98.9
Leukodystrophy 64.3 97.3
Mitochondrial 21.7 97.1
Others 27.4 86.0
TABLE 2: Sensitivity and specificity of MRI and MRS
Discussion
Traditional MRI and CT scans cannot reliably differentiate between tumorous and
nontumorous lesions and, therefore, further investigations were required. MRS is a novel
technique that can help distinguish these lesions by measuring the chemical composition of the
brain. By using specific parameters and ratios, one can reliably determine the etiology of a
particular condition without using invasive and painful procedures.
Using a combination of MRI and MRS, tumors could be reliably distinguished from non-
neoplastic lesions with a sensitivity of 91.7% and a specificity of 94.3%. Other studies agree
with our findings [8-10]. One study found MRS to be superior to an 8F-dihydroxyphenylalanine
(F-DOPA) positron emission tomography (PET) scan in differentiating these two
conditions [11]. Another study looked at differentiating tuberculomas from neoplastic lesions
and concluded that a 3.8 ppm peak could reliably differentiate the two conditions [12].
Leukodystrophies yielded a moderate to low sensitivity (64.3%) and 97.3% specificity when
using MRS as compared to clinical diagnosis. Our center does not routinely perform
histopathologic studies for this diagnosis and, therefore, this was not available. While there are
studies elucidating specific findings of leukodystrophies, the diagnostic accuracy of this
method is yet to be reported. These findings include a raised Cho/Cr ratio with a suppressed
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NAA peak in Alexander’s leukodystrophy [13] and a lower concentration of all metabolites,
except Cr, in adult onset autosomal dominant leukodystrophy [14]. Perhaps finding
sensitivities and specificities for the various types of leukodystrophies would provide more
accurate estimates but, unfortunately, this was not possible in our setup.
MRS had a poor sensitivity (35.7%) but a near-perfect specificity (98.9%) when studying
leukodystrophies as compared to clinical diagnosis. As with leukodystrophy, no previous study
has measured the diagnostic accuracy of MRS in these disorders. We did not have the data to
elucidate individual infections, however. MRS is used extensively to study the human immuno
deficiency (HIV) infection [15-16] and, in some studies, to study the hepatitis C virus (HCV)
infection of the brain [17].
MRS proved to have poor sensitivity (21.7%) but highly accurate specificity (97.1%) for
mitochondrial disorders. According to the Mitochondrial Medicine Society (MMS), various
markers are available) for this diagnosis, including lactate, NAA, and NAA/Cr levels. In fact,
NAA has been reported to be the best surrogate marker in the diagnosis of this disease [18].
Other studies agree with our assessment that MRS is not a sensitive tool to diagnose
mitochondrial disorders: in one study, only 8 out of 29 showed lactate peaks [19] while in
another, only 2 out of 11 did so [20]. In fact, in the first study, the same patient, when scanned
twice, showed a normal MRS on one try and a lactate peak in the other [19].
Several limitations apply to this study. First, we could not determine the exact etiology of each
disease. Second, this study was conducted in one center of a private hospital and, hence, a
certain demographic was observed. Third, this was a retrospective analysis and, therefore, all
associated limitations need to be taken into account.
Conclusions
A combination of MRI and MRS was highly sensitive and specific for tumors. For infections,
leukodystrophy, mitochondrial disorders and a category of “others” on the other hand, it was
highly specific but poorly sensitive.  
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